Gastrointestinal Cancer: Drugs
(asked on 23rd January 2015) - View Source
Question to the Department of Health and Social Care:
To ask Her Majesty’s Government whether Bayer made any approach to the Cancer Drug Fund to offer to reduce their price for the use of regorafenib as a third line drug for people with gastrointestinal stromal tumours.
This question was answered on 4th February 2015
We cannot provide this information as information of this nature is commercial in confidence.